Value is a concept that concerns all healthcare stakeholders.
More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market
The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.
An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo
The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.
First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.
The hepatitis-C drug is being sold under the name MyHep.
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Established products fueled at 12% jump in first-quarter sales.
A court sided with Actavis in one product-hopping lawsuit for acne drug Doryx.
Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.
Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas
Despite increasing income, many doctors are turning away from self-employment.
Teva proposes acquisition of Mylan; start-up offers BRCA testing for $249; Botox receives another label expansion
Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.
The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.
Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.
A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.
Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.
The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down
FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad
Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.
The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.
Late-stage results show Arzerra patients have a median progression-free survival rate almost double that of chemotherapy-only patients.
An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money
The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.
IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza
Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.
Apple is putting the power of clinical trials in our pockets with ResearchKit.
Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.
The British drugmaker is reviewing the patient-oriented sales model it introduced in 2011.
Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests
AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce
Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.
The drugmaker is calling on researchers to investigate PCSK9s in specific areas of interest.
The app for the smartwatch includes secure encrypted messaging.
Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times
The panel will focus on heart failure hospitalization rates associated with the diabetes medication.
For all the scientific tools that have fallen into our hands in the past few years, we are still largely falling short in our efforts to influence our audiences' behaviors.
Generic giant Mylan proposed a deal valued at $30 billion to acquire Perrigo Company.
A study said many sales presentations fail to resonate with payer audiences.
The company has received seven warning letters since 2010.
FDA accepts previously rejected Novo Nordisk insulin application; Merck HCV doublet regimen receives Breakthrough designation for patients with kidney disease; researchers say that rising costs for cancer drugs aren't reasonable
Researchers say countries that spend the most on cancer care have better outcomes, but the explanation behind improved mortality is not clear.
A more general warning encourages consumers to engage in a personal discussion with their doctor about a drug, and it promotes engagement with longer-format printed or digitally-delivered information.
Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext
The pharma sales model increasingly relies on key account managers rather than sales reps.
The cancer and immunology drug may help patients with a condition that affects two people in every one million.
The study will include DTC and DTP advertising.
Pfizer exec said biosimilar interchangeability definition not happening anytime soon; AARP launches digital health tech studies with Pfizer and UnitedHealthcare; BMS inks gene therapy collaboration deal
Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment
Walgreen alleges Endo conspired to keep generic Opana ER off the market.
Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials
Two former Teva sales representatives claim the drugmaker used speaker programs to hide kickbacks for prescribing drugs Copaxone and Azilect.
Johnson & Johnson alleged that misleading advertising threatened the $13.2 million in average weekly sales it makes during prime allergy sales season.
The government is asking consumers which ones they prefer.
Opioids lacking abuse-foiling technology will remain available.
Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused
Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.
The focus will now include cardiovascular disease.
Pfizer spent over $1 billion on ads last year; Monday's M&A activity accounted for about 25% of this year's total; Actavis is selling its Australian generics business
The drugmaker known for its massive presence in generics purchased Auspex Pharmaceuticals to bolster its growing specialty business.
Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.
The White House's National Action Plan for Reducing Antibiotic-Resistant Bacteria proposal includes $1.2 billion in funding to reduce superbug infections and develop new diagnostics.
Key contributors to the total: Sovaldi, Harvoni and Olysio
UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals
Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system
Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.
The duo hope to begin testing a new treatment within three years.
An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.
Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.
Direct-to-patient approaches can positively impact real world and late phase research programs to increase engagement, retention and data collection.
The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.
Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute
Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.
An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.
Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal
Nielsen data shows pharma spent $4.5 billion on DTC ads last year.
A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.
Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.
A study shows that greater access to healthcare and lower smoking rates have not made baby boomers healthier than their parents.
Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.
As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.
The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
Oncology and diabetes medications are expected to be major areas of growth.
At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.
The diabetes device manufacturer will soon work with Glooko's platform.
The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.
GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
Traditional tactics of connecting with physicians are quickly becoming obsolete.
Increased FDA scrutiny has not garnered trust for the new medications.
Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing
Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.
The approval follows three advisory panel reviews and a complete response letter.
The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.